Assets
| Type | Time | Amount | Unit |
|---|
Revenue
| Type | Start date | End date | Amount | Unit |
|---|
XML
See the xml submitted here:
XML: INVALID
Separator
The full data:
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns="http://www.w3.org/1999/xhtml"
xmlns:arr="http://xbrl.dcca.dk/arr"
xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
xmlns:cmn="http://xbrl.dcca.dk/cmn"
xmlns:sob="http://xbrl.dcca.dk/sob"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
xmlns:mrv="http://xbrl.dcca.dk/mrv"
xmlns:fsa="http://xbrl.dcca.dk/fsa"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:gsd="http://xbrl.dcca.dk/gsd"
xmlns:xlink="http://www.w3.org/1999/xlink"
xml:lang="en">
<link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPBalanceSheetAccountByCurrentAndLongTermFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20241001.xsd"
xlink:type="simple"/>
<xbrli:context id="ctx-1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>1</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-5">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2025-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-6">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-9">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-12">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:SharePremiumMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-15">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2024-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-21">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-17">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-19">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:SharePremiumMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-18">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2025-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-20">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2025-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:SharePremiumMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-22">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2025-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-10">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:SharePremiumMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-13">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-16">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2023-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-14">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-8">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-11">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:SharePremiumMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-25">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="fsa:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<fsa:componentOfCashFlowsIdentifier>1</fsa:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-23">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="fsa:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<fsa:componentOfCashFlowsIdentifier>1</fsa:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-26">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-01-01</xbrli:startDate>
<xbrli:endDate>2024-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="fsa:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<fsa:componentOfCashFlowsIdentifier>2</fsa:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-24">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="fsa:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<fsa:componentOfCashFlowsIdentifier>2</fsa:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-28">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-32">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>5</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-27">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">35249389</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-01-01</xbrli:startDate>
<xbrli:endDate>2025-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>2</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="dkk">
<xbrli:measure>iso4217:DKK</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<mrv:ManagementsReview contextRef="ctx-1" id="pp-value-10-1" xml:lang="en">Key figures and selected postsQ1-Q4 (2025-01-01 â 2025-12-31)⢠Gross loss amounted to kDKK -49,676 (kDKK -32,731)⢠Operating loss amounted to kDKK -55,592 (kDKK -40,367)⢠Loss before tax amounted to kDKK -58,730 (kDKK -42,336)⢠Loss for the year amounted to kDKK -53,230 (kDKK -36,836)⢠Total assets amounted to kDKK 50,055 (kDKK 23,688)⢠Equity ratio amounted to 37.1% (32.6%)⢠Earnings per share amounted to DKK -1.1 (DKK -1.74)Numbers in parenthesis are numbers from the same period in 2024.DefinitionsEquity ratio: Shareholders equity as a proportion of total assets.Earnings per share: Profit/Loss for the period divided by average number of shares.By combining diagnostics with therapy â Curasight is on a mission to improve the lives of millions of people with cancerMore than 50% of all cancer patients would at some time receive external radiation therapy. However, traditional radiation therapy also irradiates healthy tissue, leading to serious side effects. Curasightâs new type of radiation therapy solves this problem. Curasightâs technology build on the principle called Targeted Radionuclide Therapy.Curasight A/S in shortThe therapeutic platform uTREAT® is validated and supported by uTRACE®, a clinically validated uPAR PET imaging agent built on the same targeting ligand, enabling one-to-one patient selection and biodistribution confirmation under a disciplined theranostic approach.uTRACE® has been evaluated in nine clinical studies in more than 450 patients across eight solid tumor types, providing a substantial human imaging evidence base for uPAR target engagement and ligand performance. uTRACE® is a fully developed companion diagnostics for uTREAT(R).The scientific rationale â why uPAR? uPAR (urokinase-type plasminogen activator receptor) is associated with tumor invasion, angiogenesis, and metastasis and is considered a functional driver of cancer aggressiveness. Curasightâs thesis is that uPAR can be used as an âaddress labelâ to deliver targeted radiation to clinically relevant tumor biology, rather than attempting to inhibit uPAR signaling through conventional drug modalities. Rather than being limited to a single tumor type, uPAR is broadly expressed across solid tumors.This makes uPAR a scalable therapeutic target across multiple aggressive tumor types.Historically, uPAR has been difficult to exploit using conventional drug modalities. Radioligand therapy uTREAT® reframes the opportunity: instead of blocking uPAR signaling, the receptor can be used as a handle to deliver a payload of radiation directly to aggressive cancer cells and eliminate them.(Diagnostics) uTRACE®uPAR PET imaging with uTRACE® for improved imaging of cancer across several cancer types and patient selection and biodistribution confirmation. uPAR Theranostic The combination of non-invasive PET imaging (Diagnostic) and uPAR targeted radioligand therapy (Therapy) is together known at Theranostics and where uTRACE ® serves as a companion diagnostics for uTREAT®. (Therapy) uTREAT®uPAR-targeted radioligand therapy (RLT) designed to deliver a radioactive payload to uPAR-expressing tumor tissue. Pipeline and clinical focusuTREAT®: Curasightâs lead asset is uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors. In December 2025 the first patient was dosed in Curasights Phase 1 trial in glioblastoma (GBM), an aggressive brain cancer with high unmet medical need. The program is designed to generate quantitative insights on biodistribution and dosimetry that can guide subsequent clinical decisions and potential platform expansion. Top line data is expected mid-2026.Following proof-of-concept in GBM, and subject to clinical data, regulatory feedback and available resources, Curasight intends to evaluate uTREAT® in additional uPAR-expressing solid tumors and may use basket-style clinical strategies to support disciplined indication selection. Indications under consideration include non-small cell lung cancer (NSCLC), neuroendocrine tumors (NET), head and neck cancer, pancreatic cancer, and colorectal cancer.uTRACE® (imaging) is a supporting asset and operational enabler for the platform. In prostate cancer, uTRACE® is being evaluated under a collaboration signed in 2023 with Curium Pharma. Curasight leads the program and retains all rights to uTREAT® and uTRACE® outside prostate cancer.Next-generation uPAR ligands: In parallel, Curasight is advancing next-generation uPAR ligands (higher-affinity linear and macrocyclic peptide binders) intended to support future platform expansion and improve uptake at lower target density. Development timelines remain subject to progress.GMP Manufacturing: Radiopharmaceutical development requires robust clinical and manufacturing execution. Curasightâs platform benefits from GMP experience established through uTRACE® clinical use and from a shared ligand strategy across imaging and therapy, which reduces complexity and supports reproducible workflows as clinical development progresses.The RLT MarketEstablished theranostic pathways such as PSMA and SSTR2 demonstrate that disciplined target selection, patient stratification and dosimetry driven RLT can create meaningful clinical and economic impact.Curasights uPAR platform differentiates from marketed RLTâs in that it holds the potential to enable one drug to become a therapy for multiple aggressive tumor types. The theranostic approach makes it highly specific and personalized.Key facts⢠Lead value driver: uTREAT® (uPAR-targeted RLT) â Phase 1 initiated in GBM; first patient dosed in December 2025.⢠Supporting asset: uTRACE® (uPAR PET imaging) â evaluated in nine clinical studies (>450 patients) across eight solid tumor types; Phase 2 in prostate cancer led by Curium (collaboration signed in 2023).⢠Platform thesis: one target (uPAR) and one targeting ligand enabling therapy-led development with imaging support for patient selection and biodistribution confirmation.⢠Scientific origin: based on research conducted at Rigshospitalet and the University of Copenhagen led by Professor Andreas Kjær and collaborators.⢠Intellectual property: patent portfolio and pending applications reported by the Company to extend to 2043.Important informationuTREAT® is an investigational compound. Its safety and efficacy have not yet been established and it has not been approved by any regulatory authority. This section may contain forward-looking statements, including statements regarding clinical development plans and timing; actual results may differ materially due to risks and uncertainties. About high grade glioma and glioblastomaTreatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Approximately 65,000 patients in the US and EU are diagnosed annually with brain tumors of which approximately 30,000 patients are diagnosed with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, drug candidates are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive. About neuroendocrine tumorsEach year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body. About head and neck cancerHead and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years. About Non Small Cell Lung Cancer (NSCLC) Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies. About Pancreatic CancerPancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024. About Prostate cancerProstate cancer is the most common cancer in men, with approximately 640,000 new cases expected to be diagnosed annually across the US and the EU. While many tumors grow slowly, a significant proportion develop into aggressive disease that is challenging to detect and monitor with existing methods. Accurate detection and monitoring of prostate cancer remain major challenges, particularly in patients with advanced or recurrent disease. About colorectal cancerColorectal cancer (CRC) is among the most common malignancies and remains a major cause of cancer mortality. Approximately ~670,000 patients are diagnosed each year across the US and Europe. Despite effective screening in parts of the population, a substantial fraction of patients are still diagnosed with advanced disease; in the US the overall 5-year relative survival is ~63%, dropping to ~13% for distant (metastatic) disease, underscoring the need for more effective treatments for advanced CRC. Key clinical milestones 2025-2026®uTREAT â Clinical Trial Application (CTA) authorisedH1 2025®H2 2025uTREAT â fi rst patient dosed in brain cancer (GBM) ®uTREAT â preliminary eï¬ cacy data inH1 2026brain cancer (GBM) ® uTRACEâ preliminary eï¬ cacy data ph 2 trial (Curium H1 2026partnership)®uTRACE â topline results ph 2 trialH1 2026(Curium partnership) Therapeutic ProgramPre-clinicalPhase IPhase IIPhase IIISponsor: Curasight®®Diagnostic platform: uTRACE and uTREATGBMPhase IIb/III to Phase IIb/III to Phase I/IIa trial ongoingbe plannedGlioblastoma (Brain cancer)NSCLCNon-Small Cell Lung cancersPhase I/IIa trial in planningNENBasket trial* across Neuroendocrine neoplasmsselected cancer diseasesPhase IIb/III to Phase IIb/III to Completedbe plannedbe plannedApplying the theranostic approachCombining diagnostic HNSCC(uTrace) and therapy Head & Neck Cancer(uTreat)PaCPancreatic cancer*A basket trial is designed toîsimultaneously evaluate treatments for multiple tumors in a single clinical trial. Curasight will investigate cancer ®therapy with uTREAT in selected cancer diseases known to express uPAR.Partnered ProjectPre-clinicalPhase IPhase IIPhase IIISponsor: CurasightPartner: Curium Inc.®Diagnostic platform: uTRACECompleted**Ongoing PlannedProstate Cancer*)* Investigated for diagnostic performance for non-invasive classifi cation of ISUP grades among patients with localised, untreated prostate cancer.)** Investigator-initiated studyInvestigator Initiated TrialsPre-clinicalPhase I Phase II Phase IIISponsor: National University Hospital of Denmark (Rigshospitalet)®Diagnostic platform: uTRACEGBMCompletedGlioblastoma (Brain cancer)PCaCompletedProstate cancerNENCompletedResults from Neuroendocrine neoplasms®uTRACE IITs are used as supportive data inîongoingîpartner project with Curium as HNSCCCompletedwell as in potential future Head & Neck Cancerpartnering projects and in the planning of ourîtherapeutic programîwith a NSCLCtheranostic OngoingNon-Small Cell Lung cancer approach.BCCompletedBreast cancer UBCCompleted**Urinary bladder cancer )* Investigator Initiated Trails = IITs, >400 patients have received utrace in these Investigator Initiated Trials)** Completed with fewer patients than planned for technical reasonsAnalysesSEB initiated its commissioned research on June 18, 2021, and has since then continuously monitored and analyzed Curasightâs operations, platforms, markets, and competitors. SEBâs corporate page on Curasight is available at the following link:https://research.sebgroup.com/corporate/companies/2853/overviewHC Andersen Capital initiated its commissioned research on May 25, 2025, and will continuously monitor and analyze Curasightâs operations, platforms, markets, and competitors. Read more information about HC Andersen Capital on their website: https://hcandersencapital.dk/ KapitalPartner initiated its commissioned research on August 2021, and has since then continuously monitored and analyzed Curasightâs operations, platforms, markets, and competitors. KapitalPartnerâs corporate page on Curasight is available at the following link:https://kapitalpartner.dk/curasight/Corporate InformationShareholdersThe table below presents the managementâs shareholdings in Curasight.Name Votes & capital (%)1AK 2014 Holding ApS15,282UK Curacap ApS11,123Madsen Holding 2013 ApS1,954LT 2003 ApS1,235Charlotte Vedel0,166Kirsten Drejer0,127Hanne Damgaard jensen0,071. Owned by co-founder, CSO, and Board Member Andreas Kjaer2. Owned by CEO and Board Member Ulrich Krasilnikoff3. Owned by Co-founder and Director CMC, Jacob Madsen4. Owned by Deputy Chairman of the Board, Lars Trolle5. Member of the Board of Directors 6. Chair of the Board of Directors7. COOThe shareThe shares of Curasight A/S were listed on SpotlightStock Market on October 8, 2020. The short name/ticker is CURAS, and the ISIN code is DK0061295797.As of December 31, 2025, the number of shares was47,922,841 (21,148,880). All shares have equal rights tothe Companyâs assets and results.Long-term incentive programCurasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Companyâs Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (dept. chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors).For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoî (CEO), Andreas Kjær (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Aîairs) and Jacob Madsen (Director CMC).On July 30, 2024, Curasight re-issued a total of 59,132 (previously lapsed) warrants with rights to subscribe for a total of DKK 2,956.60 nominally worth of shares in the Company. 42,460 warrants will be re-issued as part of the ordinary incentive program covering the Executive Management and key employees of the Company. 16,672 warrants will be re-issued and allocated to Chair of the Board of Directors Kirsten Drejer as part of the ordinary incentive program covering the Board of Directors of the Company.RisksA number of risk factors can affect Curasightâs operations. It is therefore of great importance to consider relevant risks in addition to the Companyâs growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the disclosure document published by the Company in 2025. The document is available on Curasightâs website https://www.curasight.com/investor/rights-issue-2025/ Accounting policyThe annual report is presented in accordance with the provisions of the Danish Financial Statements Act (Ã
rsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.Auditorâs reviewThe annual report has been audited by the Companyâs auditor.Financial calendarAGM 2026 March 25, 2026Interim report Q1 2026 May 28, 2025 Interim report Q2 2026 August 27, 2026Interim report Q3 2026 November 26, 2026For further information, please contact:Ulrich Krasilnikoff, CEOE-mail: uk@curasight.comFinancial statements Income statementOperating loss before tax for the financial year of 2024 amounted to kDKK -58,730 (kDKK -42,336). The difference is due to higher clinical and development activities.Loss before depreciation, amortisation and impairments for the financial year of 2025 amounted to kDKK -54,778 (kDKK -39,553) of which staff expenses was kDKK -5,103 (kDKK -6,822). Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses. Balance sheetPer December 31, 2025, the Companyâs balance sheet amounted to kDKK 50,055 (kDKK 23,688). The assets consisted primarily of acquired IP-rights totaling ®kDKK 6,013 related to the development of uTRACE®and uTREAT and cash amounted to kDKK 35,912. The equity and liabilities consisted primarily of an equity totaling kDKK 17,936.Cash flowCurasightâs total cash flow from activities in January â December 2025 amounted to kDKK 25,901. This post was primarily affected by the Companyâs loss for the year of kDKK -52,606. Cash as of December 31, 2025, was kDKK 35,912 (kDKK 10,011). Capital resourcesAs a development stage start-up life-science company, and like other similar development stage companies, the Company has had a negative cash flow in 2025 why the company is dependent on being recapitalized or selling rights to its products against cash until reaching the point where the size of the revenue exceeds the costs resulting in a positive cash flow. The activities of the company in the future will depend on proceeds obtained from capital increases, license- and collaboration agreements or sales of rights. Please refer to note 1 to the Financial Statements.</mrv:ManagementsReview>
<gsd:NameOfReportingEntity contextRef="ctx-1" id="pp-value-3" xml:lang="en">CURASIGHT A/S</gsd:NameOfReportingEntity>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" id="pp-value-5-1" xml:lang="en">Ole Maaløes Vej</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" id="pp-value-6" xml:lang="en">3</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" id="pp-value-7" xml:lang="en">2200</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" id="pp-value-8" xml:lang="en">København N</gsd:AddressOfReportingEntityDistrictName>
<gsd:RegisteredOfficeOfReportingEntity contextRef="ctx-1" id="pp-value-9" xml:lang="en">København N</gsd:RegisteredOfficeOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1" id="pp-value-4-1">35249389</gsd:IdentificationNumberCvrOfReportingEntity>
<cmn:NameOfAuditFirm contextRef="ctx-2" id="pp-value-1-1" xml:lang="en">PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-2" id="pp-value-2-1">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="ctx-1" id="pp-value-22-1" xml:lang="en">Curasight A/S is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors.</mrv:DescriptionOfPrimaryActivitiesOfEntity>
<fsa:AcquiredPatents contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__5"
unitRef="dkk">6013000</fsa:AcquiredPatents>
<fsa:AcquiredPatents contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__5"
unitRef="dkk">6827000</fsa:AcquiredPatents>
<fsa:IntangibleAssets contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__6"
unitRef="dkk">6013000</fsa:IntangibleAssets>
<fsa:IntangibleAssets contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__6"
unitRef="dkk">6827000</fsa:IntangibleAssets>
<fsa:DepositsLongtermInvestmentsAndReceivables contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__7"
unitRef="dkk">77000</fsa:DepositsLongtermInvestmentsAndReceivables>
<fsa:DepositsLongtermInvestmentsAndReceivables contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__7"
unitRef="dkk">51000</fsa:DepositsLongtermInvestmentsAndReceivables>
<fsa:LongtermInvestmentsAndReceivables contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__8"
unitRef="dkk">77000</fsa:LongtermInvestmentsAndReceivables>
<fsa:LongtermInvestmentsAndReceivables contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__8"
unitRef="dkk">51000</fsa:LongtermInvestmentsAndReceivables>
<fsa:NoncurrentAssets contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__9"
unitRef="dkk">6090000</fsa:NoncurrentAssets>
<fsa:NoncurrentAssets contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__9"
unitRef="dkk">6878000</fsa:NoncurrentAssets>
<fsa:OtherShorttermReceivables contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__13"
unitRef="dkk">2553000</fsa:OtherShorttermReceivables>
<fsa:OtherShorttermReceivables contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__13"
unitRef="dkk">1299000</fsa:OtherShorttermReceivables>
<fsa:CurrentDeferredTaxAssets contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__14"
unitRef="dkk">5500000</fsa:CurrentDeferredTaxAssets>
<fsa:CurrentDeferredTaxAssets contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__14"
unitRef="dkk">5500000</fsa:CurrentDeferredTaxAssets>
<fsa:ShorttermReceivables contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__15"
unitRef="dkk">8053000</fsa:ShorttermReceivables>
<fsa:ShorttermReceivables contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__15"
unitRef="dkk">6799000</fsa:ShorttermReceivables>
<fsa:CashAndCashEquivalents contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__16"
unitRef="dkk">35912000</fsa:CashAndCashEquivalents>
<fsa:CashAndCashEquivalents contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__16"
unitRef="dkk">10011000</fsa:CashAndCashEquivalents>
<fsa:CurrentAssets contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__17"
unitRef="dkk">43965000</fsa:CurrentAssets>
<fsa:CurrentAssets contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__17"
unitRef="dkk">16810000</fsa:CurrentAssets>
<fsa:Assets contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__20"
unitRef="dkk">50055000</fsa:Assets>
<fsa:Assets contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__20"
unitRef="dkk">23688000</fsa:Assets>
<fsa:GrossProfitLoss contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__5"
unitRef="dkk">-49676000</fsa:GrossProfitLoss>
<fsa:GrossProfitLoss contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__5"
unitRef="dkk">-32731000</fsa:GrossProfitLoss>
<fsa:EmployeeBenefitsExpense contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__6"
unitRef="dkk">5102000</fsa:EmployeeBenefitsExpense>
<fsa:EmployeeBenefitsExpense contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__6"
unitRef="dkk">6822000</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__8"
unitRef="dkk">814000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__8"
unitRef="dkk">814000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__9"
unitRef="dkk">-55592000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__9"
unitRef="dkk">-40367000</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:OtherFinanceIncome contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__10"
unitRef="dkk">42000</fsa:OtherFinanceIncome>
<fsa:OtherFinanceIncome contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__10"
unitRef="dkk">264000</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__11"
unitRef="dkk">3180000</fsa:OtherFinanceExpenses>
<fsa:OtherFinanceExpenses contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__11"
unitRef="dkk">2233000</fsa:OtherFinanceExpenses>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__12"
unitRef="dkk">-58730000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__12"
unitRef="dkk">-42336000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:TaxExpense contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__13"
unitRef="dkk">-5500000</fsa:TaxExpense>
<fsa:TaxExpense contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__13"
unitRef="dkk">-5500000</fsa:TaxExpense>
<fsa:ProfitLoss contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__14"
unitRef="dkk">-53230000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__14"
unitRef="dkk">-36836000</fsa:ProfitLoss>
<fsa:TransferredToFromRetainedEarnings contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__21"
unitRef="dkk">-53230000</fsa:TransferredToFromRetainedEarnings>
<fsa:TransferredToFromRetainedEarnings contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__21"
unitRef="dkk">-36836000</fsa:TransferredToFromRetainedEarnings>
<fsa:ProfitLoss contextRef="ctx-1"
decimals="-3"
id="f1__s3__3__22"
unitRef="dkk">-53230000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx-4"
decimals="-3"
id="f1__s3__4__22"
unitRef="dkk">-36836000</fsa:ProfitLoss>
<fsa:Equity contextRef="ctx-9"
decimals="-3"
id="f1__s5__3__14"
unitRef="dkk">1057000</fsa:Equity>
<fsa:Equity contextRef="ctx-12"
decimals="INF"
id="f1__s5__4__14"
unitRef="dkk">0</fsa:Equity>
<fsa:Equity contextRef="ctx-15"
decimals="-3"
id="f1__s5__5__14"
unitRef="dkk">6654000</fsa:Equity>
<fsa:Equity contextRef="ctx-6"
decimals="-3"
id="f1__s5__6__14"
unitRef="dkk">7711000</fsa:Equity>
<fsa:ProfitLoss contextRef="ctx-21"
decimals="-3"
id="f1__s5__5__15"
unitRef="dkk">-53230000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx-1"
decimals="-3"
id="f1__s5__6__15"
unitRef="dkk">-53230000</fsa:ProfitLoss>
<fsa:IncreaseOfCapital contextRef="ctx-17"
decimals="-3"
id="f1__s5__3__16"
unitRef="dkk">1339000</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-19"
decimals="INF"
id="f1__s5__4__16"
unitRef="dkk">0</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-21"
decimals="-3"
id="f1__s5__5__16"
unitRef="dkk">62116000</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-1"
decimals="-3"
id="f1__s5__6__16"
unitRef="dkk">63455000</fsa:IncreaseOfCapital>
<fsa:Equity contextRef="ctx-18"
decimals="-3"
id="f1__s5__3__17"
unitRef="dkk">2396000</fsa:Equity>
<fsa:Equity contextRef="ctx-20"
decimals="INF"
id="f1__s5__4__17"
unitRef="dkk">0</fsa:Equity>
<fsa:Equity contextRef="ctx-22"
decimals="-3"
id="f1__s5__5__17"
unitRef="dkk">15540000</fsa:Equity>
<fsa:Equity contextRef="ctx-5"
decimals="-3"
id="f1__s5__6__17"
unitRef="dkk">17936000</fsa:Equity>
<fsa:Equity contextRef="ctx-7"
decimals="-3"
id="f1__s5__3__5"
unitRef="dkk">995000</fsa:Equity>
<fsa:Equity contextRef="ctx-10"
decimals="INF"
id="f1__s5__4__5"
unitRef="dkk">0</fsa:Equity>
<fsa:Equity contextRef="ctx-13"
decimals="-3"
id="f1__s5__5__5"
unitRef="dkk">30388000</fsa:Equity>
<fsa:Equity contextRef="ctx-16"
decimals="-3"
id="f1__s5__6__5"
unitRef="dkk">31383000</fsa:Equity>
<fsa:ProfitLoss contextRef="ctx-14"
decimals="-3"
id="f1__s5__5__6"
unitRef="dkk">-36836000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx-4"
decimals="-3"
id="f1__s5__6__6"
unitRef="dkk">-36836000</fsa:ProfitLoss>
<fsa:IncreaseOfCapital contextRef="ctx-8"
decimals="-3"
id="f1__s5__3__7"
unitRef="dkk">62000</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-11"
decimals="INF"
id="f1__s5__4__7"
unitRef="dkk">0</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-14"
decimals="-3"
id="f1__s5__5__7"
unitRef="dkk">13102000</fsa:IncreaseOfCapital>
<fsa:IncreaseOfCapital contextRef="ctx-4"
decimals="-3"
id="f1__s5__6__7"
unitRef="dkk">13164000</fsa:IncreaseOfCapital>
<fsa:Equity contextRef="ctx-9"
decimals="-3"
id="f1__s5__3__8"
unitRef="dkk">1057000</fsa:Equity>
<fsa:Equity contextRef="ctx-12"
decimals="INF"
id="f1__s5__4__8"
unitRef="dkk">0</fsa:Equity>
<fsa:Equity contextRef="ctx-15"
decimals="-3"
id="f1__s5__5__8"
unitRef="dkk">6654000</fsa:Equity>
<fsa:Equity contextRef="ctx-6"
decimals="-3"
id="f1__s5__6__8"
unitRef="dkk">7711000</fsa:Equity>
<fsa:ContributedCapital contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__23"
unitRef="dkk">2396000</fsa:ContributedCapital>
<fsa:ContributedCapital contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__23"
unitRef="dkk">1057000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__24"
unitRef="dkk">15540000</fsa:RetainedEarnings>
<fsa:RetainedEarnings contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__24"
unitRef="dkk">6654000</fsa:RetainedEarnings>
<fsa:Equity contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__25"
unitRef="dkk">17936000</fsa:Equity>
<fsa:Equity contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__25"
unitRef="dkk">7711000</fsa:Equity>
<fsa:ShorttermTradePayables contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__34"
unitRef="dkk">6123000</fsa:ShorttermTradePayables>
<fsa:ShorttermTradePayables contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__34"
unitRef="dkk">4155000</fsa:ShorttermTradePayables>
<fsa:ShorttermDeferredIncome contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__35"
unitRef="dkk">25060000</fsa:ShorttermDeferredIncome>
<fsa:ShorttermDeferredIncome contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__35"
unitRef="dkk">10922000</fsa:ShorttermDeferredIncome>
<fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__36"
unitRef="dkk">936000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
<fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__36"
unitRef="dkk">900000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__37"
unitRef="dkk">32119000</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__37"
unitRef="dkk">15977000</fsa:ShorttermLiabilitiesOtherThanProvisions>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__40"
unitRef="dkk">32119000</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__40"
unitRef="dkk">15977000</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx-5"
decimals="-3"
id="f1__s4__3__43"
unitRef="dkk">50055000</fsa:LiabilitiesAndEquity>
<fsa:LiabilitiesAndEquity contextRef="ctx-6"
decimals="-3"
id="f1__s4__4__43"
unitRef="dkk">23688000</fsa:LiabilitiesAndEquity>
<fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx-1" id="pp-value-39-1" xml:lang="en">20252024Staï¬ expenses(kDKK)(kDKK)2.Wages and salaries 3,434 5,063Pensions 1,095 1,250Other social security costs 54 31Other staff costs 519 478Tot al 5,102 6,822</fsa:DisclosureOfEmployeeBenefitsExpense>
<fsa:AverageNumberOfEmployees contextRef="ctx-1"
decimals="0"
id="f1__s7__5__5"
unitRef="pure">4</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx-4"
decimals="0"
id="f1__s7__6__5"
unitRef="pure">4</fsa:AverageNumberOfEmployees>
<fsa:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="ctx-1" id="pp-value-36-1" xml:lang="en">Capital resources and liquidityAs a clinical-stage life science company, the Company is focused on advancing its diagnostic 1.and therapeutic platforms through key clinical milestones. In 2025, the Company significantly strengthened its financial position by raising DKK 63.4 million in equity and expected DKK 40.0 million through new and renegotiated loan facilities. This financing provides a solid foundation for executing the Companyâs planned activities in 2026. The renegotiated loan facilities amount to a total of DKK 40 million, of which DKK 25 million are subject to several loan covenants. Management assesses that there is significant headroom in relation to these covenants and furthermore expects that all loan conditions will be complied with throughout the period. The renegotiated loan of DKK 40 million is due for repayment in December 2026 unless converted into equity. It is managementâs expectation that the loan will be converted into shares rather than repaid. Accordingly, management has included the renegotiated loan facilities in the liquidity forecast for 2026.Furthermore, the Company plans to strength the institutional investor base in 2026 to support the Companyâs activities in 2026 and 2027.Based on the financing secured in 2025, the Companyâs budget for 2026 and expected liquidity position as of 31 December 2026 are designed to support the continued advancement of both development platforms. In 2026, the Company expects to complete the Phase II clinical trial for the uTRACE diagnostic platform in prostate cancer and the Phase I clinical trial for the uTREAT therapeutic platform in glioblastoma, representing important value-creating milestones. Management continuously monitors the Companyâs liquidity position, loan covenants, capital requirements, and funding opportunities to ensure financial flexibility and alignment with the Companyâs strategic priorities. The Company also continues to evaluate additional financing and partnering opportunities to support further development beyond 2026.On this basis, the Board of Directors and Management considers the Company to be appropriately capitalized to execute its planned activities and have prepared the financial statements for 2025 on a going concern basis. Due to the obligation to repay the renegotiated loan in December 2026 is there according to the going concern assessment, a significant doubt on the Companyâs ability to continue as a going concern, even though the Management is very confident that the loan will be converted into equity, as Management consider this as a formality.Although the Board of Directors and Management based on this assessment considers that Curasight A/S will secure adequate and enough liquidity resources to finance the operations of the Company for the coming year, the above indicate that a material uncertainty exists that may cast significant doubt on the Companyâs ability to continue as a going concern.</fsa:DisclosureOfUncertaintiesRelatingToGoingConcern>
<fsa:DisclosureOfAnyUncertaintyConnectedWithRecognitionOrMeasurement contextRef="ctx-1" id="pp-value-38-1" xml:lang="en">Uncertainty concerning recognition and measurementThe Company operates in a development-stage environment, where the timing and magnitude of future cash flows are subject to inherent uncertainty. The valuation of intangible assets reflects Managementâs best estimates and judgements, prepared in accordance with the Companyâs accounting policies and based on the information available at the time. These valuations are supported by the Companyâs continued clinical progress and the execution of its development strategy. </fsa:DisclosureOfAnyUncertaintyConnectedWithRecognitionOrMeasurement>
<fsa:ProfitLoss contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__5"
unitRef="dkk">-53230000</fsa:ProfitLoss>
<fsa:ProfitLoss contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__5"
unitRef="dkk">-36836000</fsa:ProfitLoss>
<fsa:Adjustments contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__6"
unitRef="dkk">-1506000</fsa:Adjustments>
<fsa:Adjustments contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__6"
unitRef="dkk">-2717000</fsa:Adjustments>
<fsa:DecreaseIncreaseInReceivables contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__7"
unitRef="dkk">-1310000</fsa:DecreaseIncreaseInReceivables>
<fsa:DecreaseIncreaseInReceivables contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__7"
unitRef="dkk">3510000</fsa:DecreaseIncreaseInReceivables>
<fsa:DecreaseIncreaseInTradePayables contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__8"
unitRef="dkk">-2593000</fsa:DecreaseIncreaseInTradePayables>
<fsa:DecreaseIncreaseInTradePayables contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__8"
unitRef="dkk">2767000</fsa:DecreaseIncreaseInTradePayables>
<fsa:OtherAdjustmentsForDecreaseIncreaseInWorkingCapital contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__9"
unitRef="dkk">-626000</fsa:OtherAdjustmentsForDecreaseIncreaseInWorkingCapital>
<fsa:OtherAdjustmentsForDecreaseIncreaseInWorkingCapital contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__9"
unitRef="dkk">201000</fsa:OtherAdjustmentsForDecreaseIncreaseInWorkingCapital>
<fsa:CashFlowFromOperatingActivitiesBeforeFinancialItems contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__10"
unitRef="dkk">-54079000</fsa:CashFlowFromOperatingActivitiesBeforeFinancialItems>
<fsa:CashFlowFromOperatingActivitiesBeforeFinancialItems contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__10"
unitRef="dkk">-38609000</fsa:CashFlowFromOperatingActivitiesBeforeFinancialItems>
<fsa:InterestPaidClassifiedAsOperatingActivities contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__11"
unitRef="dkk">3139000</fsa:InterestPaidClassifiedAsOperatingActivities>
<fsa:InterestPaidClassifiedAsOperatingActivities contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__11"
unitRef="dkk">1046000</fsa:InterestPaidClassifiedAsOperatingActivities>
<fsa:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__12"
unitRef="dkk">-5500000</fsa:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<fsa:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__12"
unitRef="dkk">-5500000</fsa:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<fsa:CashFlowsFromUsedInOperatingActivities contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__13"
unitRef="dkk">-51718000</fsa:CashFlowsFromUsedInOperatingActivities>
<fsa:CashFlowsFromUsedInOperatingActivities contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__13"
unitRef="dkk">-34155000</fsa:CashFlowsFromUsedInOperatingActivities>
<fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-25" id="f1__s6__4__17" xml:lang="en">Change in deposits</fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-23" id="f1__s6__3__17" xml:lang="en">Change in deposits</fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-23"
decimals="-3"
id="f1__s6__3__18"
unitRef="dkk">26000</fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-25"
decimals="INF"
id="f1__s6__4__18"
unitRef="dkk">0</fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-26" id="f1__s6__4__20" xml:lang="en">Capital Increase</fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-24" id="f1__s6__3__20" xml:lang="en">Capital Increase</fsa:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-24"
decimals="-3"
id="f1__s6__3__21"
unitRef="dkk">63455000</fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx-26"
decimals="-3"
id="f1__s6__4__21"
unitRef="dkk">13164000</fsa:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<fsa:CashFlowsFromUsedInInvestingActivities contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__22"
unitRef="dkk">77619000</fsa:CashFlowsFromUsedInInvestingActivities>
<fsa:CashFlowsFromUsedInInvestingActivities contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__22"
unitRef="dkk">24086000</fsa:CashFlowsFromUsedInInvestingActivities>
<fsa:NetIncreaseDecreaseInCashAndCashEquivalents contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__27"
unitRef="dkk">25901000</fsa:NetIncreaseDecreaseInCashAndCashEquivalents>
<fsa:NetIncreaseDecreaseInCashAndCashEquivalents contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__27"
unitRef="dkk">-10069000</fsa:NetIncreaseDecreaseInCashAndCashEquivalents>
<fsa:CashAndCashEquivalentsConcerningCashflowStatement contextRef="ctx-6"
decimals="-3"
id="f1__s6__3__28"
unitRef="dkk">10011000</fsa:CashAndCashEquivalentsConcerningCashflowStatement>
<fsa:CashAndCashEquivalentsConcerningCashflowStatement contextRef="ctx-16"
decimals="-3"
id="f1__s6__4__28"
unitRef="dkk">20080000</fsa:CashAndCashEquivalentsConcerningCashflowStatement>
<fsa:CashAndCashEquivalentsConcerningCashflowStatement contextRef="ctx-5"
decimals="-3"
id="f1__s6__3__29"
unitRef="dkk">35912000</fsa:CashAndCashEquivalentsConcerningCashflowStatement>
<fsa:CashAndCashEquivalentsConcerningCashflowStatement contextRef="ctx-6"
decimals="-3"
id="f1__s6__4__29"
unitRef="dkk">10011000</fsa:CashAndCashEquivalentsConcerningCashflowStatement>
<fsa:Loans contextRef="ctx-1"
decimals="-3"
id="f1__s6__3__19"
unitRef="dkk">-14138000</fsa:Loans>
<fsa:Loans contextRef="ctx-4"
decimals="-3"
id="f1__s6__4__19"
unitRef="dkk">-10922000</fsa:Loans>
<fsa:DisclosureOfContributedCapital contextRef="ctx-1" id="pp-value-43-1" xml:lang="en">6.Share CapitalTotal nominal The share capital consists of: Quantityvalue DKKShare class A 47,922,841 2,396,142.05</fsa:DisclosureOfContributedCapital>
<fsa:CashFlowsStatement contextRef="ctx-1" id="pp-value-45-1" xml:lang="en">8.Adjustments for the cash flow statement31.12.202531.12.2024kDKKkDKKDepreciation, amortisation and impairment of intangibleassets and property, plant and equipment. 814 814Financial expenses 3,180 1,969Tax on profit or loss for the year -5,500 -5,500Tot al 1,506 -2,717</fsa:CashFlowsStatement>
<fsa:DisclosureOfContingentLiabilities contextRef="ctx-1" id="pp-value-44-1" xml:lang="en">7.Contingent liabilitiesLease commitments: Curasight A/S has entered lease agreements where the obligations in the non-terminability period amounts to DKK 77,088.</fsa:DisclosureOfContingentLiabilities>
<fsa:DisclosureOfIntangibleAssets contextRef="ctx-1" id="pp-value-41-1" xml:lang="en">4.Intangible assetsAcquired Figures in kDKKrightsCosts as at 01.01.2025 10,032Disposal 0Disposal 0Cost as at 31.12.2025 10,032Amortisation and impairment losses as at 01.01.2025 -3,205Amortisation during the year -814Amortisation and impairment losses as at 31.12.2025 -4,019Carrying amount as at 31.12.2025 6,013</fsa:DisclosureOfIntangibleAssets>
<fsa:DisclosureOfTaxExpenses contextRef="ctx-1" id="pp-value-40-1" xml:lang="en">20252024(kDKK)(kDKK)3.TaxTax on loss for the year -5,500 -5,500Deferred tax previous year 0 0Tot al -5,500 -5,500The unrecognized deferred tax asset amounts to kDKK 20,214 (kDKK 21,120) can be carried forward indefinitely. Tax has been computed at 22 percent corresponding to the current tax rate.</fsa:DisclosureOfTaxExpenses>
<fsa:DisclosureOfInvestments contextRef="ctx-1" id="pp-value-42-1" xml:lang="en">5.Non-current financial assetsFigures in kDKK DepositsCost as at 01.01.2025 51Disposals 26Disposals 0Cost as at 31.12.2025 77Carrying amount as at 31.12.2025 77</fsa:DisclosureOfInvestments>
<fsa:DisclosureOfAccountingPolicies contextRef="ctx-1" id="pp-value-46-1" xml:lang="en">9.îAccounting policiesGeneralThe annual report is presented in accordance with the provisions of the Danish Financial Statements Act (Ã
rsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class. In line with industry practice, Curasight expenses all research costs. Development costs that do not meet the definition of an asset are also expensed as incurred. Due to regulatory and other uncertainties inherent in the development of new products, development costs do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or highly probable.CurrencyThe annual report is presented in Danish kroner (DKK). On initial recognition, transactions denominated in foreign currencies are translated using the exchange rates applicable at the transaction date. Exchange rate differences between the exchange rate applicable at the transaction date and the exchange rate at the date of payment are recognised in the income statement as a financial item. Receivables, payables and other monetary items denominated in foreign currencies are translated using the exchange rates applicable at the balance sheet date. The difference between the exchange rate applicable at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest annual report is recognised under financial income or expenses in the income statement. Fixed assets and other non-monetary assets acquired in foreign currencies are translated using historical exchange rates.Income statementGross lossWith reference to section 32 of the Danish Financial Statements Act, gross profit/loss is calculated as a summary of other income minus expenses for research and development activities and other external expenses.Other incomeOther income comprises income of a secondary nature in relation to the companyâs activities, including grants and milestone payments relating to partnership agreements. Government grants relating to costs are deferred and recognised in profit or loss over the period necessary to match them with the costs that they are intended to cover.Research and development expensesResearch and development expenses comprise of costs arising from research and development activities including expenses for consumables and production.Other external expenses Other external expenses comprise expenses relating to administratrive expenses, office expenses, cost of premises, etc.Staff costsStaff expenses comprise wages and salaries as well as payroll expenses. Depreciation, amortisation and impairment lossesThe depreciation and amortisation of intangible assets and property, plant and equipment aim at systematic depreciation and amortisation over the expected useful lives of the assets. Assets are depreciated and amortised according to the straight-line method based on the following expected useful lives and residual values:Useful lives, Residual yearsvalue DKKAccuirred rights 11-20 0The basis of depreciation and amortisation is the cost of the asset less the expected residual value at the end of the useful life. Moreover, the basis of depreciation and amortisation is reduced by any impairment losses. The useful life and residual value are determined when the asset is ready for use and reassessed annually. Intangible assets and property, plant and equipment impaired in accordance with the accounting policies referred to in the âImpairment losses on fixed assetsâ section. Net financialsInterest income and interest expenses, foreign exchange gains and losses on transactions denominated in foreign currencies etc. are recognised in net financials.Tax on profit/loss for the yearThe current and deferred tax for the year is recognised in the income statement as tax on the profit/loss for the year with the portion attributable to the profit/ loss for the year, and directly in equity with the portion attributable to amounts recognised directly in equity. Balance sheetIntangible assetsAcquired rightsAquired rights are measured in the balance sheet at cost less accumulated amortisation and impairment losses. Acquired rights are amortised using the straight-line method based on useful lives, which are stated in the âDepreciation, amortisation and impairment lossesâ section. Gains or losses on the disposal of intangible assets Gains or losses on the disposal of intangible assets aredetermined as the difference between the selling price,if any, less selling costs and the carrying amount at the date of disposal. Property, plant and equipmentProperty, plant and equipment comprise other fixtures and fittings, tools and equipment. Property, plant and equipment are measured in the balance sheet at cost less accumulated depreciation and impairment losses. Cost comprises the purchase price and expenses resulting directly from the purchase until the asset is ready for use. Interest on loans arranged to finance production is not included in the cost. Property, plant and equipment are depreciated using the straight-line method based on useful lives and residual values, which are stated in the âDepreciation, amortisation and impairment lossesâ section. Gains and losses on the disposal of property, plant and equipment are determined as the difference between the selling price, if any, less selling costs and the carrying amount at the date of disposal less any costs of disposal. Assets costing less than DKK 30,000 are expensed in the year of acquisition. Impairment losses on fixed assetsThe carrying amount of fixed assets which are not measured at fair value is assessed annually for indications of impairment over and above what is reflected in depreciation and amortisation. If the companyâs realised return on an asset or a group of assets is lower than expected, this is consideredan indication of impairment. If there are indications of impairment, an impairment test is conducted of individual assets or groups of assets. The assets or groups of assets are impaired to the lower of recoverable amount and carrying amount. The higher of net selling price and value in use is used as the recoverable amount. The value in use is determined as the present value of expected net cash flows from the use of the asset or group of assets as well as expected net cash flows from the sale of the asset or group of assets after the expiry of their useful lives. Impairment losses are reversed when the reasons for the impairment no longer exist.DepositsDeposits recognised under assets comprise deposits paid to the lessor under leases entered into by the company. ReceivablesReceivables are measured at amortised cost, which usually corresponds to the nominal value, less write- downs for bad debts. Write-downs for bad debts are determined based on an individual assessment of each receivable if there is no objective evidence of individual impairment of a receivable. CashCash includes deposits in bank account.Current and deferred taxCurrent tax payable and receivable is recognised in the balance sheet as tax computed on the basis of the taxable income for the year, adjusted for tax paid on account. Deferred tax liabilities and tax assets are recognised on the basis of all temporary differences between the carrying amounts and tax bases of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is non-amortisable for tax purposes and other items where temporary differences, except for acquisitions, have arisen at the date of acquisition without affecting the net profit or loss for the year or the taxable income. In cases where the tax value can be determined according to different taxation rules, deferred tax is measured on the basis of managementâs intended use of the asset or settlement of the liability. Deferred tax assets are recognised, following assessment, at the expected realisable value through offsetting against deferred tax liabilities or elimination in tax on future earnings. Deferred tax is measured on the basis of the tax rules and at the tax rates which, according to the legislation in force at the balance sheet date, will be applicable when the deferred tax is expected to crystallise as current tax. Other debtsShort-term debts are measured at amortised cost, normally corresponding to the nominal value of such debts. Cash flow statementThe cash flow statement is prepared using the indirect method, showing cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and end of the year. Cash flows from operating activities comprise the net profit or loss for the year, adjusted for non-cash operating items, income tax paid and changes in working capital. Cash flows from investing activities comprise in connection with the acquisition and divestment of companies and financial assets as well as the purchase, development, improvement and sale of intangible assets and property, plant and equipment. Cash flows from financing activities comprise changes in the companyâs share capital and associated costs and financing from and dividends paid to shareholders as well as the arrangement and repayment of long-term payables. Cash and cash equivalents at the beginning and end of the year comprise cash. </fsa:DisclosureOfAccountingPolicies>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" id="pp-value-63-1" xml:lang="en">Statement by the Board of DirectorsWe have on this day presented the annual report for the financial year 01.01.2025 - 31.12.2025 for CURASIGHT A/S.The annual report is presented in accordance with Danish Financial Statements Act (Ã
rsregnskabsloven).In our opinion, the financial statements give a true and fair view of the companyâs assets, liabilities and financial position as at 31.12.2025 and of the results of the companyâs activities and cash flows for the financial year 01.01.2025 - 31.12.2025.We believe that the managementâs review includes a fair review of the matters dealt with in the managementâs review. The annual report is submitted for adoption by the general meeting.</sob:StatementByExecutiveAndSupervisoryBoards>
<sob:PlaceOfSignatureOfStatement contextRef="ctx-1" id="pp-value-50-1" xml:lang="en">København N</sob:PlaceOfSignatureOfStatement>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-28" id="pp-value-53-1" xml:lang="en">Kirsten Drejer</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-29" id="pp-value-55-1" xml:lang="en">Lars Trolle</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-28" id="pp-value-54" xml:lang="en">Chairperson</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-29" id="pp-value-56" xml:lang="en">Deputy chairman of the Board</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-30" id="pp-value-57-1" xml:lang="en">Charlotte Vedel</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-31" id="pp-value-59-1" xml:lang="en">Ulrich Krasilnikoff</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-30" id="pp-value-58" xml:lang="en">Board member</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-31" id="pp-value-60-1" xml:lang="en">Board member, CEO & CFO</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-32" id="pp-value-61" xml:lang="en">Andreas Kjær</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-32" id="pp-value-62-1" xml:lang="en">Board member, CSO & CMO</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-27" id="pp-value-51-1" xml:lang="en">Ulrich Krasilnikoff</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-27" id="pp-value-52" xml:lang="en">CEO</cmn:TitleOfMemberOfExecutiveBoard>
<arr:SignatureOfAuditorsPlace contextRef="ctx-1" id="pp-value-68" xml:lang="en">Hellerup</arr:SignatureOfAuditorsPlace>
<gsd:NameOfSubmittingEnterprise contextRef="ctx-1" id="pp-value-66-1" xml:lang="en">PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1" id="pp-value-67-1">33771231</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-2" id="pp-value-69" xml:lang="en">Søren Ãrjan Jensen</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-2" id="pp-value-70-1" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-3" id="pp-value-71" xml:lang="en">Kristian Højgaard Carlsen</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-3" id="pp-value-72-1" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-75-1" xml:lang="en">OpinionIn our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2025, and of the results of the Companyâs operations and cash flows for the financial year 1 January - 31 December 2025 in accordance with the Danish Financial Statements Act.We have audited the Financial Statements of Curasight A/S for the financial year 1 January - 31 December 2025, which comprise income statement, balance sheet, statement of cash flows, statement of changes in equity and notes, including a summary of significant accounting policies (âthe Financial Statementsâ).</arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" id="pp-value-76-1" xml:lang="en">Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the âAuditorâs responsibilities for the audit of the Financial Statementsâ section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:MaterialUncertaintyConcerningGoingConcernAudit contextRef="ctx-1" id="pp-value-77-1" xml:lang="en">Material Uncertainty Related to Going ConcernWe draw the attention to Note 1 in the financial statements, which describe that the budget for 2026 and the expected cash position on 31 December 2026 are dependent on renegotiated loan and additional funding. This indicates that a material uncertainty exists that may cast significant doubt on the Companyâs ability to continue as a going concern. Our opinion is not modified in respect of this matter. </arr:MaterialUncertaintyConcerningGoingConcernAudit>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-78-1" xml:lang="en">Statement on Managementâs ReviewManagement is responsible for Managementâs Review.Our opinion on the Financial Statements does not cover Managementâs Review, and we do not express any form of assurance conclusion thereon.In connection with our audit of the Financial Statements, our responsibility is to read Managementâs Review and, in doing so, consider whether Managementâs Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.Moreover, it is our responsibility to consider whether Managementâs Review provides the information required under the Danish Financial Statements Act.Based on the work we have performed, in our view, Managementâs Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Managementâs Review.</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" id="pp-value-80-1" xml:lang="en">Managementâs responsibilities for the Financial StatementsManagement is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.In preparing the Financial Statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" id="pp-value-81-1" xml:lang="en">Auditorâs Responsibilities for the Audit of the Financial StatementsOur objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:⢠Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.⢠Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companyâs internal control.⢠Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.⢠Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Company to cease to continue as a going concern.⢠Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that gives a true and fair view.We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. </arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:AuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-73" xml:lang="en">Independent auditorâs report</arr:AuditorsReportOnAuditedFinancialStatements>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-74" xml:lang="en">To the Shareholders of Curasight A/S</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1" id="f1__s0__72__15">Annual report</gsd:InformationOnTypeOfSubmittedReport>
<cmn:TypeOfAuditorAssistance contextRef="ctx-1" id="f1__s0__72__16">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" id="f1__s0__72__17" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:ReportingPeriodStartDate contextRef="ctx-1" id="f1__s0__72__20">2025-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx-1" id="f1__s0__72__21">2025-12-31</gsd:ReportingPeriodEndDate>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1" id="f1__s0__72__22">2024-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx-1" id="f1__s0__72__23">2024-12-31</gsd:PredingReportingPeriodEndDate>
<gsd:DateOfGeneralMeeting contextRef="ctx-1" id="f1__s0__72__36">2026-03-25</gsd:DateOfGeneralMeeting>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx-1" id="f1__s0__72__40" xml:lang="en">Ulrik Bangsbo Hansen</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<fsa:ClassOfReportingEntity contextRef="ctx-1" id="f1__s0__72__45">Reporting class B</fsa:ClassOfReportingEntity>
<fsa:SelectedElementsFromReportingClassC contextRef="ctx-1" id="f1__s0__72__46">true</fsa:SelectedElementsFromReportingClassC>
<fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="ctx-1" id="f1__s0__72__48">true</fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod>
<gsd:TelephoneNumberOfReportingEntity contextRef="ctx-1" id="f1__s0__72__59" xml:lang="en">22830160</gsd:TelephoneNumberOfReportingEntity>
<gsd:HomepageOfReportingEntity contextRef="ctx-1" id="f1__s0__72__61">www.curasight.com</gsd:HomepageOfReportingEntity>
<gsd:EmailOfReportingEntity contextRef="ctx-1" id="f1__s0__72__62" xml:lang="en">info@curasight.com</gsd:EmailOfReportingEntity>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx-1" id="f1__s0__72__77">2026-04-26</sob:DateOfApprovalOfAnnualReport>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" id="f1__s0__72__171" xml:lang="en">Strandvejen 44</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" id="f1__s0__72__172" xml:lang="en">2900 Hellerup</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" id="f1__s0__72__175">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
<arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" id="f1__s0__72__176">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
<arr:SignatureOfAuditorsDate contextRef="ctx-1" id="f1__s0__72__186">2026-02-26</arr:SignatureOfAuditorsDate>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-2" id="f1__s0__72__191">mne33226</cmn:IdentificationNumberOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-3" id="f1__s0__72__208">mne44112</cmn:IdentificationNumberOfAuditor>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-3" id="f1__s0__72__210">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameOfAuditFirm contextRef="ctx-3" id="f1__s0__72__212" xml:lang="en">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
</xbrli:xbrl>